Responses
Regular and young investigator award abstracts
Clinical trials in progress
344 Phase 3 trial of pembrolizumab and enzalutamide versus enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) (KEYNOTE-641)
Compose a Response to This Article
Other responses
No responses have been published for this article.
